Archives — July 2017 back to current month (7)
A company with Canadian medical cannabis provider Aphria's backing is doing a reverse takeover on the Canadian Securities Exchange and expects to begin trading on July 26.
A U.S. biotech developing vaccines to fight a number of infectious diseases has generated promising preclinical results with a platform therapy targeting influenza, and expects to enter the clinic with a similar platform compound targeting Ebola in 2018.
News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company.
In its corporate update for Q2/17, a Canada-based biotech targeting neurological disorders including Alzheimer's disease informed investors of advancements in several programs, including designation of a second validated lead compound in development.
If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them.
A Vancouver-based biotech firm that aims to become the first preventative medicine company is expected to commence trading on the Canadian Securities Exchange July 14.
With enrollment complete in its Phase 3 trial of a compound that treats post-operative pain, and an infusion of cash from a new partnership with a major pharmaceutical corporation, one analyst has initiated coverage of this California-based company, and another has reiterated his investment thesis.
|"We believe this newer Alzheimer's theory creates a path to develop a unique disease-modifying Alzheimer's treatment, PMN's PMN310, which has best-in-class potential."|
|"INO's INO-5150 generated T-cell responses in 60% of trial subjects."|
|"RP is currently in discussions with potential partnerships focused not just on the firm's injector, but also on its regenerative medicine therapies."|